A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin.

Abstract:

BACKGROUND:The plant milk thistle and silymarin has been traditionally used as a natural remedy for the treatment of various ailments including neurological disorders such as Alzheimer's and Parkinson's disease and cerebral ischemia for over 2000 years. OBJECTIVE:In this article we review the neuroprotective effects of silymarin against various neurological dysfunctions. RESULTS:The neuroprotective effects conferred by silymarin include modulation of various antioxidant mechanisms, and several kinases involved in cell signaling pathways, inhibition of the inflammatory response generated during neurodegeneration, neurotropic effects, regulation of neurotransmitters and inhibition of apoptosis. The ease of availability, comparative low cost and safety profile provide additional advantages for the use of this compound as a potent drug with immense clinical benefit. However, there is a growing need for improvements in the bioavailability of silymarin and related products, and more consistent and reliable human trials are required to accurately validate the neuroprotective efficacy of this natural compound. CONCLUSION:The promising outcomes of the studies mentioned in this review provide renewed insight into the clinical relevance of silymarin in a variety of neurodegenerative disorders where neuroinflammation and oxidative stress are pathologically relevant to disease progression.

journal_name

Curr Drug Targets

journal_title

Current drug targets

authors

Devi KP,Malar DS,Braidy N,Nabavi SM,Nabavi SF

doi

10.2174/1389450117666161227125121

subject

Has Abstract

pub_date

2017-01-01 00:00:00

pages

1529-1536

issue

13

eissn

1389-4501

issn

1873-5592

pii

CDT-EPUB-80605

journal_volume

18

pub_type

杂志文章,评审
  • Triterpene derivatives as inhibitors of protein involved in the inflammatory process: molecules interfering with phospholipase A2, cycloxygenase, and lipoxygenase.

    abstract::Over the past years, there was an explosion in the knowledge of the protein target and molecular mechanism associated with various disease types and in the new research of drugs of natural origin. The key idea is to evaluate bioactive natural products interacting with protein domains of different genetic origin but st...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945011794815284

    authors: Braca A,Dal Piaz F,Marzocco S,Autore G,Vassallo A,De Tommasi N

    更新日期:2011-03-01 00:00:00

  • Microdialysis approach to study serotonin outflow in mice following selective serotonin reuptake inhibitors and substance P (neurokinin 1) receptor antagonist administration: a review.

    abstract::Classical antidepressant drugs such as Selective Serotonin Reuptake Inhibitors (SSRIs) display several disadvantages, e.g., the onset of action (2 to 3 weeks) to start clinical benefits is too long, and a significant proportion of patients do not respond to this monotherapy. Several strategies have been proposed to ov...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945006775515428

    authors: Guiard BP,Lanfumey L,Gardier AM

    更新日期:2006-02-01 00:00:00

  • Cyclization in opioid peptides.

    abstract::Endogenous opioid peptides have been studied extensively as potential therapeutics for the treatment of pain. The major problems of using natural opioid peptides as drug candidates are their poor receptor specificity, metabolic instability and inability to reach the brain after systemic administration. A lot of synthe...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450111314070008

    authors: Piekielna J,Perlikowska R,Gach K,Janecka A

    更新日期:2013-06-01 00:00:00

  • Pharmacological therapies for pediatric and neonatal ALI/ARDS: an evidence-based review.

    abstract::Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threating conditions still lacking a definite therapy and carrying a high mortality and morbidity, especially in children and infants. Albeit respiratory assistance and supportive therapies are crucial for ALI/ARDS, many drugs have been pr...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945012800675687

    authors: De Luca D,Piastra M,Tosi F,Pulitanò S,Mancino A,Genovese O,Pietrini D,Conti G

    更新日期:2012-06-01 00:00:00

  • Portals and Web-Based Resources for Virtual Screening.

    abstract::Virtual screening for active compounds has become an essential step within the drug development pipeline. The computer based prediction of compound binding modes is one of the most time and cost efficient methods for screening ligand libraries and enrich results of potential drugs. Here we present an overview about cu...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450117666160201105806

    authors: Krüger J,Thiel P,Merelli I,Grunzke R,Gesing S

    更新日期:2016-01-01 00:00:00

  • HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET.

    abstract::The HIV-1 transactivator Tat protein plays a key role in AIDS pathogenesis. Besides the Tat role as activator of HIV-1 transcription, it exerts several important functions on infected and uninfected cells. In fact, HIV-1 Tat is released by infected cells and is taken up by neighboring cells. In this way it regulates e...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450116666150825110658

    authors: Chiozzini C,Toschi E

    更新日期:2016-01-01 00:00:00

  • New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets.

    abstract::The etiopathogenesis of Crohn's disease (CD) and ulcerative Colitis (UC), the two major forms of inflammatory bowel disease (IBD), is still unknown. Although the exact cause and mechanisms of both IBD have yet to be completely understood, it is widely accepted that both CD and UC result from an inappropriate immune re...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945008784221170

    authors: Stefanelli T,Malesci A,Repici A,Vetrano S,Danese S

    更新日期:2008-05-01 00:00:00

  • Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation.

    abstract::Inflammation plays a central role in chronic obstructive pulmonary disease (COPD). COPD related inflammation is less responsive to inhaled steroids compared to asthma. There are three major novel anti-inflammatory approaches to the management of COPD. The first approach is phosphodiesterase inhibitors, such as roflumi...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450111314020008

    authors: Loukides S,Bartziokas K,Vestbo J,Singh D

    更新日期:2013-02-01 00:00:00

  • Fetal determinants of type 2 diabetes.

    abstract::Type 2 diabetes, which has dramatically increased during the last decade normally results from a combination of pancreatic beta cell dysfunction and insulin resistance. One of the most recent risk factors identified for type 2 diabetes is a sub-optimal fetal and neonatal environment. Numerous human epidemiological stu...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945007781386866

    authors: Reusens B,Ozanne SE,Remacle C

    更新日期:2007-08-01 00:00:00

  • Notch-associated microRNAs in cancer.

    abstract::The Notch signaling plays a key role in cell differentiation, survival, and proliferation through diverse mechanisms. Thus, alterations of the Notch signaling can lead to a variety of disorders including human malignancies. Of considerable interest, recent evidence indicates that there is a significant cross-talk betw...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/13894501113149990188

    authors: Mo YY,Tang H,Miele L

    更新日期:2013-09-01 00:00:00

  • The Role of Type 2 Fibroblast Growth Factor in Periodontal Therapy.

    abstract::The prevalence of periodontitis is around 20-50% of global population. If not treated, it can cause of tooth loss. Periodontal treatment aims at preserving the patient's teeth from various methods, including infection control and restoring lost periodontal tissue. The periodontium has great biological regenerative pot...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121999201105152639

    authors: Mohammadipour HS,Forouzanfar F,Forouzanfar A

    更新日期:2020-11-05 00:00:00

  • Sphingolipid metabolism enzymes as targets for anticancer therapy.

    abstract::Treatment with anti-cancer agents in most cases ultimately results in apoptotic cell death of the target tumor cells. Unfortunately, tumor cells can develop multidrug resistance, e.g., by a reduced propensity to engage in apoptosis by which they become insensitive to multiple chemotherapeutics. Ceramide. the central m...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450043345452

    authors: Kok JW,Sietsma H

    更新日期:2004-05-01 00:00:00

  • Cervical cancer: are there potential new targets? An update on preclinical and clinical results.

    abstract::According to international guidelines, treatment of cervical cancer (CC) consists of surgery in early stages and of chemoradiation in locally advanced disease. Metastatic disease is usually treated with palliative chemotherapeutic regimens, but cytostatic drugs present significant side effects and show limited activit...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450115666141010145547

    authors: Tomao F,Di Tucci C,Imperiale L,Boccia SM,Marchetti C,Palaia I,Muzii L,Panici PB

    更新日期:2014-01-01 00:00:00

  • PDZ Structure and Implication in Selective Drug Design against Cystic Fibrosis.

    abstract::PDZ domains play an essential role in a number of cellular processes by facilitating protein scaffolding and assembly of protein complexes. These domains consist of 80 to 90 amino acids and are found to recognize short C-terminal sequences of target proteins. Protein complex formation between PDZ target molecules can ...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450116666141219120125

    authors: Holcomb J,Spellmon N,Trescott L,Sun F,Li C,Yang Z

    更新日期:2015-01-01 00:00:00

  • Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology.

    abstract:BACKGROUND:The Coronavirus Disease 2019 (COVID-19) is becoming the major health issue in recent human history with thousands of deaths and millions of cases worldwide. Newer research and old experience with other corona-viruses highlighted a probable underlying mechanism of disturbance of the renin-angiotensin system (...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121666201020154033

    authors: Vieira C,Nery L,Martins L,Jabour L,Dias R,Simões E Silva AC

    更新日期:2020-10-20 00:00:00

  • Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials.

    abstract::Rituximab has demonstrated a major effect in B-cell lymphoma and in a wide range of autoimmune disorders. Unfortunately, the blood-brain-barrier excludes the disorders restricted to the central nervous system (CNS) from the action of rituximab. The progressive phase of multiple sclerosis (MS) is a prototypical CNS aut...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450115666141029234644

    authors: Bonnan M,Ferrari S,Bertandeau E,Demasles S,Krim E,Miquel M,Barroso B

    更新日期:2014-01-01 00:00:00

  • Therapeutic Applications of Liposomal Based Drug Delivery and Drug Targeting for Immune Linked Inflammatory Maladies: A Contemporary View Point.

    abstract::Immune-based inflammatory diseases involve immune related dysregulation in different sites of body, which includes rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, atherosclerosis, etc. Advancements in molecular research have facilitated investigation of their pathogenesis that is involved in infl...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450118666170414113926

    authors: Rahman M,Beg S,Verma A,Kazmi I,Patel DK,Anwar F,Al Abbasi FA,Kumar V

    更新日期:2017-01-01 00:00:00

  • Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.

    abstract::Overexpression of the human epidermal growth factor receptor 2 (HER2) is identified in approximately 25- 30% of breast cancers and indicates a poor prognosis. Trastuzumab, the anti-HER2 monoclonal antibody (mAb), has shown significant clinical effects selectively in HER2-overexpressing metastatic breast cancer (MBC) w...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/13894501113149990161

    authors: Huang Y,Fu P,Fan W

    更新日期:2013-07-01 00:00:00

  • Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders.

    abstract::The adenosine pathway is a powerful evolutionarily selected mechanism aimed at a fine modulation of inflammatory responses and protection of tissues from injuries. Adenosine exerts its modulatory effects via interaction with G protein-coupled receptors, designated as A(1), A(2A), A(2B) and A(3). In this regard, extrac...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945012800564095

    authors: Antonioli L,Colucci R,La Motta C,Tuccori M,Awwad O,Da Settimo F,Blandizzi C,Fornai M

    更新日期:2012-06-01 00:00:00

  • Advances in antiplatelet therapy for stroke prevention: the new P2Y12 antagonists.

    abstract::Thrombus formation at a site of arterial injury (eg, rupture of an atherosclerotic plaque in a carotid artery), a crucial step in the pathogenesis of cerebral ischemia, is initiated by the adhesion of platelets to the arterial wall. In vivo, activated platelets release adenosine diphosphate (ADP), whose binding to the...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945010790711987

    authors: Giossi A,Pezzini A,Del Zotto E,Volonghi I,Costa P,Ferrari D,Padovani A

    更新日期:2010-03-01 00:00:00

  • Potential options to treat hypertriglyceridaemia.

    abstract::Hypertriglyceridaemia is associated with insulin resistance, hypertension, obesity and diabetes. The management of hypertriglyceridaemia and atherogenic dyslipidaemias increasingly involves the use of several drugs for different aspects of the metabolic syndrome. This review highlights the agents for treatment of bloo...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945009787846380

    authors: Viljoen A,Wierzbicki AS

    更新日期:2009-04-01 00:00:00

  • The link between Hepatic Vitamin A Metabolism and Nonalcoholic Fatty Liver Disease.

    abstract::The liver is essential for the control of glucose and lipid metabolism. Excessive accumulation of fat in the liver disturbs its function and leads to the development of fatty liver diseases. The nonalcoholic fatty liver disease (NAFLD) is a common type of fatty liver disease found in patients who have not consumed sig...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450116666150325231015

    authors: Chen G

    更新日期:2015-01-01 00:00:00

  • Is Galanin a Promising Therapeutic Resource for Neural and Nonneural Diseases?

    abstract:BACKGROUND:Galanin (GAL) constitutes a family of neuropeptides composed of four peptides: (i) galanin (GAL), (ii) galanin-message associated peptide (GAMP), (iii) galanin-like peptide (GALP), and (iv) alarin. GAL contains 29/30 amino acids, and its biological action occurs through the interactions with its various rece...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450121666200225112055

    authors: Oliveira Volpe CM,Vaz T,Rocha-Silva F,Villar-Delfino PH,Nogueira-Machado JA

    更新日期:2020-01-01 00:00:00

  • Diacylglycerol kinases as emerging potential drug targets for a variety of diseases.

    abstract::Diacylglycerol (DAG) kinase (DGK) modulates the balance between the two signaling lipids, DAG and phosphatidic acid (PA), by phosphorylating (consuming) DAG to yield PA. Ten mammalian DGK isozymes have been identified to date. In addition to two or three cysteine-rich C1 domains (protein kinase C-like zinc finger stru...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945008785132394

    authors: Sakane F,Imai S,Kai M,Yasuda S,Kanoh H

    更新日期:2008-08-01 00:00:00

  • Osteopontin; as a target molecule for the treatment of inflammatory diseases.

    abstract::It has been well recognized that inflammatory responses are part of pathogenesis for various disorders such as autoimmune diseases. For example, multiple sclerosis (MS) is an inflammatory demyelinating disease of central nervous system that is presumably caused by activated T cells specific for myelin antigens. Rheuma...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945010790980321

    authors: Morimoto J,Kon S,Matsui Y,Uede T

    更新日期:2010-04-01 00:00:00

  • Nutrition in adult patients with inflammatory bowel disease.

    abstract::Seventy five percent of hospitalized patients with Crohn's disease suffer from malnutrition. One third of Crohn's disease patients have a body mass index below 20. Sixty percent of Crohn's disease patients have sarcopenia. However some inflammatory bowel disease (IBD) patients are obese or suffer from sarcopenic-obesi...

    journal_title:Current drug targets

    pub_type: 杂志文章

    doi:10.2174/1389450115666140930150047

    authors: Hebuterne X,Filippi J,Schneider SM

    更新日期:2014-01-01 00:00:00

  • Targeting transcription: a new concept of anti-inflammatory therapy of airway diseases.

    abstract::Most pathological conditions that result in human diseases are associated with altered gene expression. With the advent of new technologies that might control gene expression and a broader knowledge of transcription factors and pathways, new strategies have emerged that offer promising first results for therapeutical ...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945006777435326

    authors: Quarcoo D,Hamelmann E

    更新日期:2006-06-01 00:00:00

  • Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect.

    abstract::The incidence and mortality of malignant tumors are on the rise, which has become the second leading cause of death in the world. At present, anti-tumor drugs are one of the most common methods for treating cancer. In recent years, with the in-depth study of tumor biology and related disciplines, it has been gradually...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450120666190402145325

    authors: Wang S,Zhou D,Xu Z,Song J,Qian X,Lv X,Luan J

    更新日期:2019-01-01 00:00:00

  • Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.

    abstract::Vascular Disrupting Agents (VDA) are a potential new class of oncology drugs that have garnered attention recently as a number of these agents have entered into Phase 2-3 studies. Currently available data suggest how the subsequent evolution of these agents into clinical practice may proceed, with new therapeutic para...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/138945011798829366

    authors: Spear MA,LoRusso P,Mita A,Mita M

    更新日期:2011-12-01 00:00:00

  • Possible Effects of Dietary Anthocyanins on Diabetes and Insulin Resistance.

    abstract::Diabetes is reaching epidemic proportions worldwide. Many dietary compounds have been found to exert health beneficial effects against different pathologies including diabetes. Most bioactive compounds have been identified in fruits and vegetables and their mechanisms of action explored both in vitro and in vivo. In p...

    journal_title:Current drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1389450116666151001105230

    authors: Turrini E,Ferruzzi L,Fimognari C

    更新日期:2017-01-01 00:00:00